This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Houston Pathologist Named Pathologist Of The Year

National Pathologist Association Recognizes Philip T. Cagle, MD, FCAP

NORTHFIELD, Ill., Oct. 14, 2013 /PRNewswire-USNewswire/ -- Philip T. Cagle, MD, FCAP, of Houston, Texas, was named the 2013 Pathologist of the Year by the College of American Pathologists.  Dr. Cagle was recognized at special ceremony held on October 13, 2013 at the College's annual meeting, CAP'13—THE Pathologists' Meeting.


Dr. Cagle received the award, the CAP's highest honor, in recognition for his outstanding contributions as editor of the College's award-winning peer-reviewed journal— Archives of Pathology & Laboratory Medicine.  He was also recognized with the CAP Distinguished Patient Care Award for serving as co-chair in the development of the CAP lung cancer biomarker evidence-based guideline.  The recommendations mark a significant breakthrough in the diagnosis and treatment of lung cancer and were a joint project with the International Association for the Study of Lung Cancer and the Association for Molecular Pathology.

"I am deeply humbled and honored to be recognized by the College of American Pathologists, an organization dedicated to the pursuit of excellence in laboratory medicine," said Dr. Cagle.  "It is a distinct privilege to accept the Pathologist of the Year award and the Distinguished Patient Care award on behalf of my esteemed colleagues at the CAP."

Currently, Dr. Cagle is the S. Donald Greenberg chair and director of pulmonary pathology for the Houston Methodist Hospital; he also is professor of pathology at the Weill Cornell Medical College in New York City.  Throughout his 30-year career, Dr. Cagle has provided editorial counsel to peer-reviewed publications, received academic appointments, and has presented research across the globe.

With his undergraduate degree in biology from Lambuth College in Jackson, Tenn., Dr. Cagle earned his medical degree with a pathology fellowship from the University of Tennessee College of Medicine in Memphis. Following pathology residency at Baylor College of Medicine in Houston, where he was appointed chief resident in year four, Dr. Cagle completed a post-doctoral fellowship in pulmonary research at the University of British Columbia, Vancouver. Later he studied molecular diagnostics at the cellular level in workshop training at the Tufts University School of Medicine in Boston. 

The American Board of Pathology certifies Dr. Cagle in clinical and anatomic pathology; he holds medical licensure in Texas and Tennessee.

About Pathologists and Pathology Pathologists are physicians who use laboratory medicine and technology to identify and diagnose disease. They work with primary care physicians and others on the patient care team to guide treatment plans. In fact, more than 70 percent of all decisions about diagnosis, treatment, hospital admission, and discharge rest on the pathologist's report.

About the CAP As the leading organization for board-certified pathologists, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. With more than 18,000 physician members, the CAP has led laboratory accreditation for more than 50 years with more than 7,500 CAP-accredited laboratories in 50 countries. Find more information about the CAP at Follow CAP on Twitter: @pathologists.

SOURCE College of American Pathologists

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs